Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma.
Hose D, Ray S, Rößler S, Thormann U, Schnettler R, de Veirman K, Khassawna TE, Heiss C, Hild A, Zahner D, Alagboso F, Henss A, Beck S, Emde-Rajaratnam M, Burhenne J, Bamberger J, Menu E, de Bruyne E, Gelinsky M, Kampschulte M, Rohnke M, Wenisch S, Vanderkerken K, Hanke T, Seckinger A, Alt V. Hose D, et al. Among authors: burhenne j. J Hematol Oncol. 2025 Jan 24;18(1):11. doi: 10.1186/s13045-025-01663-9. J Hematol Oncol. 2025. PMID: 39856743 No abstract available.
Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg-IFNα-2a as Treatment for Chronic Hepatitis Delta.
Lampertico P, Bogomolov PO, Chulanov V, Stepanova T, Morozov V, Allweiss L, Dandri M, Burhenne J, Blank A, Ciesek S, Elsner C, Dittmer U, An Q, Manuilov D, Da BL, Flaherty JF, Urban S, Wedemeyer H. Lampertico P, et al. Among authors: burhenne j. Liver Int. 2025 Feb;45(2):e70008. doi: 10.1111/liv.70008. Liver Int. 2025. PMID: 39853842 Clinical Trial.
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma.
Hose D, Ray S, Rößler S, Thormann U, Schnettler R, de Veirman K, El Khassawna T, Heiss C, Hild A, Zahner D, Alagboso F, Henss A, Beck S, Emde-Rajaratnam M, Burhenne J, Bamberger J, Menu E, de Bruyne E, Gelinsky M, Kampschulte M, Rohnke M, Wenisch S, Vanderkerken K, Hanke T, Seckinger A, Alt V. Hose D, et al. Among authors: burhenne j. J Hematol Oncol. 2024 Dec 18;17(1):128. doi: 10.1186/s13045-024-01636-4. J Hematol Oncol. 2024. PMID: 39695697 Free PMC article.
Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers.
Rohr BS, Krohmer E, Foerster KI, Burhenne J, Schulz M, Blank A, Mikus G, Haefeli WE. Rohr BS, et al. Among authors: burhenne j. Clin Pharmacokinet. 2024 Apr;63(4):469-481. doi: 10.1007/s40262-024-01350-x. Epub 2024 Feb 23. Clin Pharmacokinet. 2024. PMID: 38393578 Free PMC article. Clinical Trial.
241 results